A Dose Ascending, Study To Examine The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of GSK233705B.
Status:
Completed
Trial end date:
2007-10-11
Target enrollment:
Participant gender:
Summary
GSK233705 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being
developed for the treatment of chronic obstructive pulmonary disease. This is a randomised,
double-blind, placebo-controlled, dose ascending, parallel group study to examine the safety,
tolerability, pharmacokinetics and pharmacodynamics of twice daily inhaled doses of
GSK233705B for 7 days, in COPD subjects.